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BACKGROUND: Prediction of neonatal respiratory morbidity may be RESULTS: A total of 883 images were collected, but 17.3% were
useful to plan delivery in complicated pregnancies. The limited predictive
performance of the current diagnostic tests together with the risks of an
invasive procedure restricts the use of fetal lung maturity assessment.
OBJECTIVE: The objective of the study was to evaluate the perfor-
mance of quantitative ultrasound texture analysis of the fetal lung
(quantusFLM) to predict neonatal respiratory morbidity in preterm and
early-term (<39.0 weeks) deliveries.
STUDY DESIGN: This was a prospective multicenter study
conducted in 20 centers worldwide. Fetal lung ultrasound images were
obtained at 25.0e38.6 weeks of gestation within 48 hours of delivery,
stored in Digital Imaging and Communication in Medicine format, and
analyzed with quantusFLM. Physicians were blinded to the analysis. At
delivery, perinatal outcomes and the occurrence of neonatal respira-
tory morbidity, defined as either respiratory distress syndrome or
transient tachypnea of the newborn, were registered. The performance
of the ultrasound texture analysis test to predict neonatal respiratory
morbidity was evaluated.Cite this article as: Palacio M, Bonet-Carne E, Cobo T,
et al. Prediction of neonatal respiratory morbidity by
quantitative ultrasound lung texture analysis: a multi-
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196.e1 American Journal of Obstetrics& Gynecology AUGUST 2017discarded because of poor image quality or exclusion criteria, leaving 730
observations for the final analysis. The prevalence of neonatal respiratory
morbidity was 13.8% (101 of 730). The quantusFLM predicted neonatal
respiratory morbidity with a sensitivity, specificity, positive and negative
predictive values of 74.3% (75 of 101), 88.6% (557 of 629), 51.0%
(75 of 147), and 95.5% (557 of 583), respectively. Accuracy was
86.5% (632 of 730) and positive and negative likelihood ratios were
6.5 and 0.3, respectively.
CONCLUSION: The quantusFLM predicted neonatal respiratory
morbidity with an accuracy similar to that previously reported for other
tests with the advantage of being a noninvasive technique.
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ultrasoundeonatal respiratory morbidityN (NRM) due to of either respira-
tory distress syndrome or transient
tachypnea of the newborn is the most
common complication in infants born
preterm and even early term (<39
weeks).1-3 Assessment of fetal lung
maturity for the prediction of NRMmay
be relevant, particularly after 34 weeks of
gestation, when the risk of NRM ranges
from 5% to 20%, to better assess the risk/beneﬁt ratio of elective delivery in late
pregnancy complications4-6 and/or with
the use of corticoisteroids.7,8
In current clinical practice, the eval-
uation of the risk of NRM relies on the
study of different components of the
amniotic ﬂuid which requires an
amniocentesis.9,10
Prediction of fetal lung maturity using
fetal ultrasound has long been proposed
as a noninvasive alternative to amnio-
centesis.11,12 Several approaches using
computer analysis of fetal lung ultra-
sound images have been attempted over
the last 25 years, including gray-scale
measurements,13,14 lung tissue mo-
tion,15,16 or the relationship between
image features of fetal lung vs placental
or liver tissue.17
These studies generally showed a good
correlation with NRM, but the diagnosticaccuracy was insufﬁcient for clinical use.
However, over recent years, image reso-
lution of fetal ultrasound and computer
image processing has evolved immensely.
Quantitative texture analysis is a
powerful technique that can be used to
extract information frommedical images
and to quantify tissue changes not visible
to the human eye, allowing the training
of computer programs that may predict
clinical events.18,19 Earlier studies re-
ported that texture analysis can be
applied to fetal lung ultrasound images
and to correlate with both gestational
age20 and the results of fetal lung matu-
rity testing of the amniotic ﬂuid.21 In a
recent single-center study, we tested
software based on quantitative texture
analysis of fetal lung (quantusFLM)
trained to predict NRM. The software
achieved a predictive accuracy similar to
FIGURE 1
Fetal lung image acquisition and delineation
A, Lateral axial transverse section of the fetal thorax at the level of the 4-chamber section of the fetal
heart. B, Region of interest delineated.
Palacio et al. Ultrasound prediction of neonatal respiratory morbidity. Am J Obstet Gynecol 2017.
FIGURE 2




Images for analysis 
n= 730 
Discarded aŌer image quality control: insuﬃcient 
magnificaƟon, calipers, obviously blurred images, or 
obvious acousƟc shadows 
n=135 
Excluded aŌer clinical review: neonatal sepsis, umbilical artery 
pH < 7.00, hemodynamic failure, anemia (hemoglobin < 12 g/dL),  
postnatal structural or chromosomal abnormaliƟes and 
meconium aspiraƟon 
n=18 
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maturity testing of the amniotic ﬂuid.22
Herein we report the results of a large
multicenter study designed to evaluate
the performance of quantusFLM to
predict NRM. Fetal lung ultrasound
images were obtained for analysis within
48 hours of delivery in a large cohort
of pregnancies at 25.0e38.6 weeks of
gestation. Neonatal respiratory out-
comes were prospectively recorded and
the performance of the software to pre-
dict NRM was analyzed.
Material and Methods
This was a prospective multicenter
study involving 20 centers. Patients
were recruited from June 2011 to
December 2014. Eligible cases included
pregnancies between 25.0-38.6 weeks
of gestation and for which an ultra-
sound was obtained within 48 hours of
delivery.
Cases were considered noneligible if
corticosteroids were used for lung
maturity between the ultrasound and
delivery, when the maternal body mass
index was 35 kg/m2, and when fetuses
had known congenital malformations.
Furthermore, neonates with the
following conditions were excluded:
neonatal sepsis, an umbilical artery
pH <7.00, hemodynamic failure,
symptomatic anemia (hemoglobin <12
mg/dL), a postnatal diagnosis of struc-
tural or chromosomal abnormalities,
and meconium aspiration. These con-
ditions could directly predispose or
lead to NRM, irrespective of lung
maturity.
Ultrasound images were obtained
following a detailed acquisition proto-
col. Brieﬂy, an axial section of the fetal
thorax at the level of the 4-chamber
cardiac view was magniﬁed by adjusting
the depth, but not the zoom option,
until the thorax occupied about two-
thirds of the screen, avoiding obvious
acoustic shadows from the fetal ribs
(Figure 1A). Images were acquired
without any type of postprocessing
manipulation such as smoothing, color
Doppler, or any calipers or pointers.
The use of tissue harmonic imaging
and adjustment of image settings
such as gain, frequency, and time-gaincompensation were left to the discre-
tion of the ultrasound operator per-
forming the ultrasound scan.
Before starting recruitment, each
center submitted a minimum of 5
ultrasound images of the fetal lung
that were reviewed by imaging
engineers (E.B.-C. and A.P.-M.), ac-
cording to this acquisition protocol, toAUGUST 2017 Ameriensure that quality criteria were ful-
ﬁlled. If not, further images were
requested. All study images were
collected and stored in the original
Digital Imaging and Communication
in Medicine format and sent to the
coordinator via a ﬁle transfer protocol.
Digital Imaging and Communication
in Medicine scans were anonymized,can Journal of Obstetrics& Gynecology 196.e2
TABLE 1
Clinical characteristics of the women included in the study
Total (n ¼ 685)
GA range at scan, wks
(25.0e33.6) (n ¼ 145) (34.0e38.6) (n ¼ 540)
Maternal age 32.3 (5.8) 31.4 (5. 8) 31.3 (5.8)
Nulliparity 340 (49.6%) 70 (48.3%) 270 (50%)
Ethnicity
Caucasian 400 (58.4%) 93 (64.1%) 307 (56.9%)
Black 40 (5.8%) 9 (6.2%) 31 (5.7%)
Asian 44 (6.4%) 0 44 (8.2%)
Hispanic 121 (17.7%) 24 (16.6%) 97 (18.0%)
Other 53 (7.7%) 18 (12.4%) 35 (6.5%)
Multiple pregnancy 65 (9.5%) 21 (14.5%) 44 (8.1%)
Maternal or fetal relevant conditions
Preterm labor 48 (7%) 26 (17.9%) 22 (4.1%)
PPROM 158 (23.1%) 70 (48.3%) 88 (16.3%)
Preeclampsia 116 (16.9%) 40 (27.6%) 76 (14.1%)
IUGR 148 (21.6%) 32 (22%) 116 (21.5%)
Pregestational diabetes 15 (2.2%) 3 (2.1%) 12 (2.2%)
Antepartum hemorrhage 10 (1.5%) 3 (2.1%) 7 (1.3%)
Othera 160 (23.4%) 31 (21.4%) 129 (23.9%)
Data are mean (SD) or n (percentage) when appropriate.
GA, gestational age; IUGR, intrauterine growth restriction; PPROM, preterm premature rupture of membranes.
a Hypothyrodism, hypertensive disorders, placenta previa, lupus, human immunodeficiency virus positive, assessment of fetal well-being, and fetal presentation.
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patient.
To track the scan, a new random
number was generated for each new
image. Lung images for the study were
then inspected for image quality control
by the engineer’s team and discarded if
one or more of the requirements
previously mentioned were not ful-
ﬁlled. Images passing the quality criteria
were then loaded via the Internet
through a restricted access to the com-
mercial software web site and delineated
using the quantusFLM web interface
(www.quantusﬂm.com; Transmural
Biotech, Barcelona, Spain).
Delineations were performed by
either the same clinicians acquiring the
images at each participating center or by
research clinicians at the coordinating
center. Delineation of the region of in-
terest included the largest possible
area of the fetal lung proximal to the196.e3 American Journal of Obstetrics& Gynecoltransducer, avoiding the heart and great
vessels (Figure 1B). The web software
contained an automatic ﬁlter to accept
the delineation only when at least
400 pixels were included.
Delineated ultrasound images were
then analyzed automatically with quan-
tusFLM. Features of the software used by
quantusFLM have been described in
detail elsewhere.22 The software contains
algorithms that analyze the textural
patterns of the delineated area in the
ultrasound image. These algorithms
have been trained bymeans of a machine
learning approach to estimate the prob-
ability of NRM, using hundreds of cases
of fetal lung ultrasound images in which
the occurrence of NRM was known.
The software used in this study utilizes
different sequences of texture features
adapted to gestational age ranges.16
Therefore, gestational age in weeks was
not used to calculate any a priori risk ofogy AUGUST 2017NRM but to decide the speciﬁc algo-
rithm used to calculate the probability of
NRM. The software used in this study
provided categorical results (ie, either
high or low risk for NRM).
For each recruited case, the centers
prospectively recorded the maternal
baseline characteristics and the neonatal
outcomes in a database purposely
designed for this study. Anonymized
clinical information from each case was
submitted to the coordinator through a
customized ﬁle transfer protocol and
stored in a database available only to the
clinical researchers of this project (M.P.
and T.C.), who conﬁrmed eligibility
criteria and the absence of exclusion
criteria for each case. Analysis of
neonatal clinical information was su-
pervised by a neonatologist (F.B.). The
study protocol was approved by the co-
ordinator’s Institutional Review Board
(2011/6291, 2013/8892).
TABLE 2
Perinatal and neonatal outcomes of the newborns included in the study
Variables Total (n ¼730)
Gestational age at scan, wks
(25.0e33.6) (n ¼ 164) (34.0e38.6) (n ¼ 566)
Gestational age at delivery, wks 36.0 (2.6) 31.4 (2.2) 37.2 (1.2)
Ultrasound-to-delivery lapse of time, d 0.6 (0.7) 0.7 (0.7) 0.6 (0.6)
Mode of delivery
Spontaneous vaginal delivery 294 (40.3%) 50 (30.5%) 244 (43.1%)
Operative vaginal delivery 48 (6.6%) 4 (2.4%) 44 (7.8%)
Nonelective cesarean delivery 125 (17.1%) 36 (22.0%) 89 (15.7%)
Elective casarean delivery 263 (36.0%) 74 (45.1%) 189 (33.4%)
Birthweight, g 2517 (760) 1554 (486) 2796 (575)
Female sex 365 (50.0%) 70 (42.7%) 295 (52.1%)
Apgar at 5 min <7 10/729 (1.4%) 7/163 (4.3%) 3/566 (0.5%)
pH UA 7.00 to <7.10 18/479 (3.8%) 5/124 (4%) 13/355 (3.7%)
Hyperbilirrubinemia (phototherapy) 152 (20.8%) 86 (52.4%) 66 (11.7%)
Other relevant conditions
Apnea 20 (2.7%) 20 (12.2%) 0
Bronchopulmonary displasia 8 (1.1%) 8 (4.9%) 0
Persistent pulmonary hypertension 3 (0.4%) 2 (1.2%) 1 (0.2%)
Intraventricular hemorrhage (III or IV) 3 (0.4%) 3 (1.8%) 0
Necrotizing enterocolitis 3 (0.4%) 3 (1.8%) 0
Neonatal death <28 days 3 (0.4%) 3 (1.8%) 0
NICU admission 242 (33.2%) 148 (90.2%) 94 (16.6%)
Length of stay at NICU 18.7 (19.5) 25.5 (21.4) 8.2 (9.0)
Discharged alive from NICU 239/242 (98.8%) 145/148 (98.0%) 94/94 (100%)
Data are mean (SD) or n (percentage) when appropriate.
UA, umbilical artery; NICU, neonatal intensive care unit.
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care in the participating institutions
and were enrolled in a speciﬁc protocol
for the evaluation of fetal lung maturity,
in studies involving the use of fetal
ultrasound, or in studies in which
ultrasound was used as part of the clin-
ical management approved by the local
review boards. All patients included gave
written informed consent for the use of
ultrasound images and perinatal data.
None of the observations reported here
has been previously used in another
study.
The primary clinical outcome of the
study was NRM, including respiratory
distress syndrome (RDS) or transienttachypnea of the newborn. Respiratory
distress syndrome was deﬁned based on
clinical criteria, including grunting,
nasal ﬂaring, tachypnea, and chest wall
retraction, or the need for supplemental
oxygen together with typical chest radi-
ography ﬁndings and admission to the
neonatal intensive care unit for respira-
tory support.2 Transient tachypnea of
the newborn was diagnosed based on
early respiratory distress (isolated
tachypnea, rare grunting, minimal
retraction) and a chest X-ray showing
hyperaeration of the lungs and promi-
nent pulmonary vascular patterns.23
The performance of quantusFLM to
predict NRM was analyzed by theAUGUST 2017 Americlinical researchers of this project (M.P.
and T.C.) by matching quantitative ul-
trasound analysis and clinical outcome.
Descriptive statistical methods were used
to summarize the distribution of all the
variables; for continuous variables, mean
and SD values were obtained; and, for
categorical variables, frequencies and
percentages were reported. Descriptive
statistics were performed with R lan-
guage (R Foundation for Statistical
Computing, Vienna, Austria, 2015;
https://www.R-project.org).
Results
A total of 883 cases were recruited. Of
these, 135 (15.3%) were excluded aftercan Journal of Obstetrics& Gynecology 196.e4
TABLE 3
Characteristics of the respiratory support and respiratory morbidity
Characteristics Total (n ¼ 730)
Gestational age at scan, wks
(25.0e33.6) (n ¼ 164) (34.0e38.6) (n ¼ 566)
Need for respiratory support (any) 115 (15.8%) 89 (54.3%) 26 (4.6%)
Oxygen therapy 40% 55 (7.5%) 37 (22.6%) 18 (3.2%)
CPAP 117 (16%) 94 (57.3%) 23 (4.1%)
NIV/BPAP 23 (3.2%) 22 (13.4%) 1 (0.2%)
Intubation required 31 (4.3%) 28 (17.1%) 3 (0.5%)
Days of intubation (if any) 6 (9.4) 6.7 (9.9) 1.8 (1.5)
High-frequency ventilation 12 (1.6%) 10 (6.1%) 2 (0.4%)
Surfactant use 34 (4.7%) 32 (19.5%) 2 (0.4%)
Doses of surfactant (if any) 1.4 (0.7) 1.4 (0.7) 2 (1.4)
Neonatal respiratory morbidity 101 (13.8%) 72 (43.9%) 29 (5.1%)
Data are mean (SD) or n (percentage) when appropriate.
CPAP, continuous positive airway pressure; NIV/BPAP, noninvasive ventilation/bilevel positive airway pressure.
Palacio et al. Ultrasound prediction of neonatal respiratory morbidity. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orgimage quality control and 18 (2.0%)
were excluded because of 1 or more
clinical exclusion criteria (42 of 164,
25.6%, in the 25e33.6 weeks group
and 111 of 566, 19.6%, in the
34.0e38.6 weeks group), leaving a total
of 730 images for analysis (Figure 2).
The ﬁnal number of cases included perTABLE 4
quantusFLM performance to predict ne
Characteristics T
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196.e5 American Journal of Obstetrics& Gynecolcenter and the ultrasound equipment
locally used are described in the sup-
plemental material (Supplemental
Tables 1 and 2).
The clinical characteristics of the
pregnant women enrolled in the study
and the relevant conditions for which
ultrasound was indicated are detailed inonatal respiratory morbidity
otal (n ¼ 730)
Geatational age, w
(25.0e33.6) (n ¼





86.6% (632/730) 75.6% (124/164)
74.3% (75/101) 79.2% (57/72)
88.6% (557/629) 72.8% (67/92)
51% (75/147) 69.5% (57/82)
95.5% (557/583) 81.7% (67/82)
6.5 2.9
0.3 0.3
morbidity. Am J Obstet Gynecol 2017.
ogy AUGUST 2017Table 1. The study included the
following: 17 women (2.5%) at <28
weeks; 128 women (18.7%) at 28.0 to
<34.0 weeks of gestation; 176 women
(25.7%) at 34.0 to <37.0 weeks of
gestation; and 364 women (53.1%) at
37.0 weeks of gestation. Perinatal
and neonatal outcomes and theks














Summary of performance of invasive tests in amniotic fluid used to predict
neonatal respiratory morbidity (summarized from Table 3S)
Ac Se Sp PPV NPV
quantusFLM 86.5% 74.3% 88.6% 51% 95.5%
L/S 81.6% 74.6% 82.5% 34.1% 96.4%
PG 57.5% 82.7% 54.4% 18.0% 96.3%
LBC 75.4% 84.2% 74.4% 27.9% 97.6%
TDxII 78.7% 88.5% 77.7% 28.5% 98.5%
Ac, accuracy; L/S, lecithin/sphingomyelin ratio; LBC, lamellar body count; NPV, negative predictive value; PG, phosphatidyl-
glycerol; PPV, positive predictive value; Se, sensitivity; Sp, specificity; TDxII, surfactant/albumin ratio.
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are shown in Tables 2 and 3, respectively.
The prevalence of NRM was 13.8%
(101 of 730), of which 66.3% (67 of 101)
were diagnosed as RDS and 33.7% (34 of
101) as transient tachypnea of the
newborn. All newborns diagnosed with
RDS were treated with at least 1 of the
following: oxygen higher than 40%,
continuous positive airway pressure, or
noninvasive ventilation, high-frequency
ventilation and an endotracheal tube
for invasive ventilation, or surfactant use.
The quantusFLM analysis predicted
the occurrence of NRM with a sensi-
tivity, speciﬁcity, positive predictive
value, and negative predictive value of 75
of 101 (74.3%), 557 of 629 (88.6%), 75
of 147 (51.0%), and 557 of 583 (95.5%),
respectively. Accuracy was 86.6% (632
of 730), and the positive and negative
likelihood ratios were 6.5 and 0.3,
respectively. The predictive performance
stratiﬁed by gestational age is shown in
Table 4.
Comment
Principal findings of the study
The main ﬁnding of this large multi-
center study is that quantitative texture
analysis of fetal lung ultrasound images
predicted NRM with a similar accuracy
to that of laboratory tests using amniotic
ﬂuid, which have reported sensitivities
and speciﬁcities ranging from 74% to
89% and from 54% to 89%, respec-
tively,9,24,25 although a wide range of
ﬁgures has been reported (Table 5 and
Supplemental Table 3). Furthermore,the risk of respiratory neonatal
morbidity observed in this study was
similar to that reported in a large cohort
study including late preterm and
early term infants recently published
(Supplemental Table 4).
Results of the study in the context
of other observations
Several attempts have been made to
predict fetal lung maturity using ultra-
sound images. Serizawa and Maeda13
and Maeda et al14 compared the ultra-
sonic gray-level histogram width of the
fetal lung and liver, while Bhanu Prakash
et al17 compared the values for the fetal
lungs to those of the liver. La Torre et al16
correlated several patterns of fetal
breathing movements with fetal lungs
maturity tests, and Tekesin et al26 eval-
uated the mean gray value of fetal lungs.
The accuracy identifying NRM in
all these studies has ranged from 73%
to 96%. However, no prospective
studies have been conducted after them
to validate the associations observed
(Supplemental Table 3). The approach
used in this study was different from
previous attempts to noninvasively
assess fetal lung maturity.
The method used herein is based on
the combination of texture extraction
with machine learning methods, allow-
ing the identiﬁcation of texture patterns
in the ultrasound image that correlate
with the clinical outcome. This approach
has been shown to be reliable and robust
to small variations in the conditions of
the image acquisition, including depthAUGUST 2017 Ameriand changes in the gain of the image and
does not need other tissues withwhich to
be compared (placenta, fetal liver,.).20
In addition, a previous pilot study re-
ported on the ability of this noninvasive
technology to predict NRM.22
Clinical implications
Liggins and Howie27 stated that the use
of antenatal corticosteroids could
enhance fetal lung maturity in preterm
pregnancies; as a result, corticosteroid
use is common practice with pregnan-
cies up to 34 weeks of gestation.28-30
Now the question as to whether late
preterm fetuses may beneﬁt from such
an intervention is on the rise.
The practice of testing for fetal lung
maturity is extremely variable world-
wide, being widely used in some areas
and completely ignored in others. Esti-
mation of fetal lung maturity might
reduce the use of corticosteroids in late
preterm deliveries (34e36 weeks of
gestation), for which the risk of NRM is
relevant but relatively low, ranging from
10% to 20%.
As recently shown, steroids decrease
by one-third the occurrence of NRM in
late preterm deliveries,8,31-34 and the
number needed to treat to reduce one
case of NRM in the circumstances
described is 25.8 These ﬁndings have
resulted in the publication of a Society
for Maternal-Fetal Medicine statement
on the use of antenatal corticosteroids
in the late preterm period35; it recom-
mends treatment under the strict inclu-
sion criteria of the Antenatal Late
Preterm Steroids study, while warns
against overtreatment in those cases that
do not meet the inclusion criteria.
Even if mid- and long-term follow-up
of babies exposed to corticosteroids has
shown no adverse effects or no beneﬁts
in some studies,36-39 antenatal cortico-
steroids might be associated with
potential side effects related to over-
exposure later in life,40-42 particularly in
those babies who will be delivered at
term.43,44 A substantial proportion of
fetuses treated with corticosteroids are
delivered long after 1 week of the initial
dose or even at term.45-50 Rescue doses
are debatable,51,52 and the beneﬁts and
risks have to be evaluated when repeatedcan Journal of Obstetrics& Gynecology 196.e6
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course was given early in pregnancy53-55
or if an early term elective cesarean de-
livery is planned.56 Thus, strategies to
deﬁne the target population are urged.
On the other hand, the fear of over-
treatment has to be counterbalanced
against the fact that restrictive messages
may limit the use of corticosteroids in
those cases for which the intervention
has been proven to be of beneﬁt and for
which additional information from
quantusFLM is of limited value (ie,
preterm delivery at <32 weeks). For
instance, some data showed that among
cases with potential beneﬁt, only 80%
received one dose and 70% received
two doses.57 On the contrary, there are
other studies reporting that a wide use
of corticosteroids might not be of
beneﬁt in all countries.58
All these aspects have been discussed
in recent reviews; therefore, the issue
remains controversial.59,60 It is in this
context that the selection of a low-risk
group for respiratory morbidity by a
noninvasive tool might reduce exposure
in a large number of pregnancies,
avoiding the risks of overexposure in an
unselected population and optimizing
intervention in those cases for which it is
needed.
Additionally, a common argument
against testing for fetal lung maturity is
that there is or is not a clear indication
for elective preterm delivery and there-
fore, the results of fetal lung maturity
testing would not be of help.4,61 This
view might be challenged by studies
reporting that about 23% of late-
preterm deliveries had no clear indica-
tion for delivery62 or that they were
delivered after a non-evidence-based
indication.63 Therefore, a fraction of
complicated pregnancies may fall within
a gray zone, for which elective delivery
may be considered as an option when
there is not a strict indication according
to clinical protocols or guidelines.64 In
these cases, information about fetal lung
maturity might be of help to plan
delivery.
Likewise, access to advanced neonatal
care is not readily available in all clinical
settings, even in high-resource countries.
In these circumstances, knowing the196.e7 American Journal of Obstetrics& Gynecolrisks of respiratory morbidity with an
acceptable accuracy might help clini-
cians and parents to make more
balanced decisions and/or to determine
themost appropriate place for delivery.65
Finally, among the reasons for avoid-
ing fetal lung maturity testing may be the
fear for complications of amniocentesis,
reported to occur in 0.7% of cases66,67 as
well as medical costs and/or maternal
discomfort. This perception and,
consequently, the attitude of physicians
and parents seeking information about
fetal lung maturity might be reconsid-
ered if this information can be obtained
with a noninvasive test.
Strengths and limitations
The results of this multicenter study are
in line with those obtained in a previous
smaller study in which the technology
was prospectively and blindly evaluated
in a single center in 144 patients.22 These
ﬁndings and the multicenter nature of
the study support the fact that, provided
the quality criteria in the acquisition of
the images are respected, the test is robust
and yields similar performances in
different clinical settings, enhancing the
likelihood that results are generalizable.
However, this study has some limita-
tions. The method tested in this study
uses an indirect approach to estimate
lung maturity. By deﬁnition, prenatal
prediction of NRM is hampered by the
fact that the outcome is largely, but not
exclusively, determined by the fetal lung
maturity status. Thus, in circumstances
such as neonatal sepsis, congenital
anomalies potentially affecting lung
function, or intrapartum hypoxic-
ischemic events, newborns with normal
lung maturity in utero may present res-
piratory impairment. Also, speciﬁc
conditions such as fetal growth restric-
tion, multiple pregnancy, diabetes, or
premature rupture of the membranes
were not analyzed separately. Differences
in the performance of quantusFLM in
these subgroups cannot be excluded and
requires further research.
On the other hand, the performance
of the software for each speciﬁc gesta-
tional age was not assessed in this
study because the algorithms were
not designed to predict NRM for eachogy AUGUST 2017speciﬁc gestational age. Future algo-
rithms with 1- or 2-week gestational age
intervals would be more precise,
althoughwhether this could improve the
accuracy reported herein remains to be
assessed.
Regarding the mode of delivery, the
rate of cesarean section was high, around
50%. This is due to the fact that to meet
inclusion criteria, delivery had to occur
within 48 hours of the image acquisition.
Therefore, planned cesarean sections
might be overrepresented in our study
population although this rate could be
comparable to some settings. Besides,
according to clinical practice, elective
and no-elective cesarean deliveries are
more frequent in preterm pregnancies.
Finally, despite that the ultrasound
image required to perform the test was
an axial section of the thorax, considered
as a standard section, a relatively high
number of images were eventually dis-
carded because of the lack of compliance
with the quality criteria requisites. This
stresses the fact that obtaining a valid
ultrasound axial section of the fetal
thorax at late gestation might not always
be straightforward, and in particular
cases, the test might require special care
or training to ensure an optimal image
acquisition.
Conclusion
In summary, the results of this large
multicenter study are consistent with the
ﬁndings of a pilot study on the ability of a
noninvasive technology to predict NRM
from fetal lung ultrasound images.22 The
technology also showed an accuracy
similar to that of biochemical tests in
amniotic ﬂuid previously reported.
Therefore, quantusFLM provides a
noninvasive tool that might help clini-
cians in the decision-making process. n
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SUPPLEMENTAL TABLE 1
Number of images included in each center
Center n ¼ 730 %
BCNatal (Spain) 182 24.9
UZ Leuven (Belgium) 77 10.5
Hradec Kralove (Czech Republic) 64 8.8
Sahlgrenska University Hospital (Sweden) 48 6.6
Clı´nica el Prado Medellin (Colombia) 47 6.4
Hospal University Puerta del Mar (Spain) 44 6.0
Althaia (Spain) 40 5.5
Consorci Sanitari Terrassa (Spain) 40 5.5
University of Chile Hospital Chile (Chile) 33 4.5
Perinatology Research Branch (United States) 33 4.5
Hospital La Paz (Madrid) 28 3.8
Hospital San Cecilio (Spain) 25 3.4
KK Women’s and Children’s Hospal (Singapore) 23 3.2
Children’s and Women’s Specialty Hospital of
Queretaro (Mexico)
14 1.9
Royal Prince Alfred Hospital (Australia) 12 1.6
Fernandez Hospital (India) 8 1.1
University of Wisconsin (United States) 4 0.6
Hospital Virgen Arrixaca (Spain) 4 0.6
UTHSC (United States) 2 0.3
Hospital Nostra Sra Meritxell (Andorra) 2 0.3
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SUPPLEMENTAL TABLE 2
Ultrasound equipment used in the study in alphabetical order
Equipment n ¼ 730 %
Aloka
Aloka 4000 33 4.5
General Electrics
Voluson 730 214 29.3
Voluson E6 56 7.7
Voluson S6 45 6.2
Voluson E8 123 16.8
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SUPPLEMENTAL TABLE 3
Diagnostic performance of non-invasive and invasive tests in amniotic fluid used to predict neonatal respiratory
morbidity
N Ac Sen Sp PPV NPV
Noninvasive tests
Gray-level histogram13,14 22/47 — 86 72 — —
Fetal breathing movements15,16 —/43 — 92 85 92 80
Liver-to-lung texture17 750/1000 73-96 — — — —
quantusFLM22 29/144 86 86 87 62 96
quantusFLM (present study) 101/730 86 74 88 51 95
Invasive tests25,68-72
Lecitin/esphingomielin ratio
Bowie 5/52 85 80 85 36 98
Ashwood 17/187 84 82 85 35 98
Dalence 12/122 89 92 89 48 99
Fakhoury 4/28 96 75 100 100 96
Greenspoon 7/70 80 71 81 29 96
Lee 14/141 92 64 95 60 96
Karcher 13/201 88 62 89 29 97
Hagen 29/140 81 48 89 54 87
Rusell 23/294 84 96 83 32 100
Neerhof 100/833 76 81 76 32 96
Phosphatidilglicerol
Karcher 13/204 69 92 67 16 99
Hagen 21/113 73 86 71 40 96
Rusell 16/240 80 94 79 24 99
Neerhof 100/833 47 80 42 15 94
Lamellar bodies count
Bowie 8/56 75 88 73 35 97
Ashwood 28/247 91 71 93 57 96
Dalence 16/130 96 75 99 92 97
Fakhoury 4/28 100 100 100 100 100
Greenspoon 7/62 90 100 89 54 100
Lee 14/157 94 79 95 61 98
Karcher 13/219 76 85 75 18 99
Haymond 12/184 62 92 60 14 99
Neerhof 100/833 66 88 63 25 97
TDxII-FLM
Karcher 13/218 78 92 78 21 99
Haymond 12/194 66 83 65 14 98
Hagen 29/140 77 90 74 47 100
Rusell 24/301 89 96 88 42 100
The outcome generally tested was RDS.
Ac, accuracy; n, RDS/total; NPV, negative predictive value; PPV, positive predictive value; RDS, respiratory distress syndrome; Sen, sensitivity; Sp, specificity.
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SUPPLEMENTAL TABLE 4
Prediction of neonatal respiratory morbidity by gestational age at 34.0e38.6 weeks
GA threshold, wks 34 35 36 37 38
True positives 0 390 719 1002 1206
True negatives 80,221 76,911 71,763 61,889 41,624
False positives 0 3310 8458 18332 38597
False negatives 1346 956 627 344 140
Accuracy 98% 95% 89% 77% 53%
Sensitivity 0% 29% 53% 74% 90%
Specificity 100% 96% 89% 77% 52%
Positive predictive value 0% 11% 8% 5% 3%
Negative predictive value 98% 99% 99% 99% 100%
Data are extracted from Hibbard et al2 (n ¼ 81,567, NRM, n ¼ 1346). All figures are numbers or percentage where stated.
GA, gestational age at delivery.
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